These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Antiproteolytic activity in human coronary arteries affected by long-dating atherosclerosis. Fornasari PM; Gratton L; Gamba G Boll Soc Ital Biol Sper; 1976 Jun; 52(11):761-3. PubMed ID: 1016624 [No Abstract] [Full Text] [Related]
24. Effect of epsilon-aminocaproylamino acids on fibrin formation. Bruzgo I; Midura-Nowaczek K; Bruzgo M; Kaczyńska J; Roszkowska-Jakimiec W Acta Pol Pharm; 2006; 63(2):149-52. PubMed ID: 17514879 [TBL] [Abstract][Full Text] [Related]
25. Tissue repair in presence of locally applied inhibitors of fibrinolysis. Kwaan HC; Astrup T Exp Mol Pathol; 1969 Aug; 11(1):82-8. PubMed ID: 5821816 [No Abstract] [Full Text] [Related]
26. [On local fibrinolysis in leg ulcer]. Hadlich J; Piper HG Z Haut Geschlechtskr; 1968 Oct; 43(19):805-10. PubMed ID: 5723217 [No Abstract] [Full Text] [Related]
27. [Angioedema is caused by a defect in C1-inhibitor synthesis]. Jaworska H; Gregorek H; Madaliński K Przegl Lek; 2000; 57(9):483-8. PubMed ID: 11199871 [TBL] [Abstract][Full Text] [Related]
28. Effect of epsilon-aminocaproylaminoacids on the activity of proteolytic enzymes. Bruzgo I; Midura-Nowaczek K; Roszkowska-Jakimiec W; Jasielczuk J Acta Pol Pharm; 2001; 58(2):137-40. PubMed ID: 11501792 [TBL] [Abstract][Full Text] [Related]
29. [Disseminated intravascular coagulation]. Levi M; de Jonge E; ten Cate H Ned Tijdschr Geneeskd; 2000 Mar; 144(10):470-5. PubMed ID: 10726156 [TBL] [Abstract][Full Text] [Related]
30. Measurement of fibrinolytic activity after epsilon-aminocaproic acid administration in rats (Rattus norvegicus). Gogjian MA; Barry KJ; Stein BM Lab Anim Sci; 1981 Dec; 31(6):710-1. PubMed ID: 7343767 [TBL] [Abstract][Full Text] [Related]
32. Chronic angioedema. Three relevant cases. Sánchez Palacios A; Schamann Medina F; García Marrero JA Allergol Immunopathol (Madr); 1998; 26(4):195-8. PubMed ID: 9816408 [TBL] [Abstract][Full Text] [Related]
33. A new type of acquired C1 inhibitor deficiency associated with systemic lupus erythematosus. Cacoub P; Frémeaux-Bacchi V; De Lacroix I; Guillien F; Kahn MF; Kazatchkine MD; Godeau P; Piette JC Arthritis Rheum; 2001 Aug; 44(8):1836-40. PubMed ID: 11508436 [TBL] [Abstract][Full Text] [Related]
34. Inhibitory properties of bull seminal plasma proteinase inhibitors. Zelezná B; Havranová M; Cechová D; Sedláková E Hoppe Seylers Z Physiol Chem; 1980; 361(3):461-3. PubMed ID: 6900579 [No Abstract] [Full Text] [Related]
35. A case of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. Bouillet L; Ponard D; Rousset H; Cichon S; Drouet C Br J Dermatol; 2007 May; 156(5):1063-5. PubMed ID: 17381464 [No Abstract] [Full Text] [Related]
36. [Studies on the use of p-aminomethyl benzoic acid ethyl ester as antifibrinolytic agent]. Markwardt F; Klöcking HP; Vogel G Z Gesamte Inn Med; 1967 Oct; 22(19):569-74. PubMed ID: 5596621 [No Abstract] [Full Text] [Related]
37. Hereditary angioedema: the clinical syndrome and its management in the United States. Frank MM Immunol Allergy Clin North Am; 2006 Nov; 26(4):653-68. PubMed ID: 17085283 [TBL] [Abstract][Full Text] [Related]
38. The pathogenesis of hereditary angioedema. Davis AE Transfus Apher Sci; 2003 Dec; 29(3):195-203. PubMed ID: 14572810 [TBL] [Abstract][Full Text] [Related]
39. Effects of divided doses of steroids on side effects, cytokines, and activation of complement and granulocytes, coagulation and fibrinolysis after OKT3. Bemelman FJ; Buysmann S; Wilmink JM; Surachno S; Hack CE; Schellekens PT; ten Berge RJ Transplant Proc; 1994 Dec; 26(6):3096-7. PubMed ID: 7527944 [No Abstract] [Full Text] [Related]
40. Utilization of complement testing in clinical medicine. Abdul-Aziz K; Faizal AA Saudi Med J; 2006 Nov; 27(11):1775-7. PubMed ID: 17106567 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]